Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background: Patients with schizophrenia have excess cardiovascular morbidity and mortality. Previous studies suggest that this may be partly due to inadequate somatic treatment and care, such as non-optimal use of lipid-lowering and antihypertensive pharmacotherapy, but longitudinal studies on such aetiological pathways are scarce. Method: We investigated the use of lipid-lowering and antihypertensive pharmacotherapy, and the risk of hospitalization for and death from coronary heart disease and stroke among patients with schizophrenia in a birth cohort of 12 939 subjects (Helsinki Birth Cohort Study). This cohort was followed for over 30 adult years by using national databases on cardio- and cerebrovascular hospitalizations and mortality and on reimbursement entitlements and use of drugs for treatment of hypertension, dyslipidaemia, coronary heart disease and diabetes. Results: Individuals with schizophrenia had a higher risk of hospitalization for coronary heart disease [hazard ratio (HR) 1.65, 95% confidence interval (CI) 1.03–2.57], and mortality from this disease was markedly higher (HR 2.92, 95% CI 1.70–5.00), particularly among women (p=0.001 for women, p=0.008 for men). Women with schizophrenia had also marginally increased stroke mortality (p=0.06). However, patients with schizophrenia used less lipid-lowering (odds ratio 0.47, 95% CI 0.27–0.80) and antihypertensive drug treatment (HR 0.37, 95% CI 0.22–0.61). Conclusions: In this longitudinal study, coronary heart disease morbidity was increased and coronary heart disease mortality markedly increased in patients, especially in women with schizophrenia. These patients nevertheless received less antihypertensive and lipid-lowering treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A study from Helsinki (Lahti et al. 2012) found a 0.37-fold use of antihypertensive drugs and a 0.47-fold use of lipid-lowering drugs compared to the general population.”
From Excess early mortality in schizophrenia. (2014) · cites this paper as Lahti et al. 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081
Cause-Specific Excess Deaths Associated With Underweight, Overweight, and Obesity
Flegal, K. M., Graubard, B. I., Williamson, D. F., & Gail, M. H. (2007) · JAMA · doi:10.1001/jama.298.17.2028 · Cited by 1,542 · cited 2×
“Nonetheless, the 2004 US mortality data showed that 36.9% of deaths were still from cardiovascular diseases, including 19.4% from coronary heart disease (CHD) (Flegal et al. 2007).”
BackgroundInfluentialTiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Schizophrenia and increased risks of cardiovascular disease
Hennekens, C. H., Hennekens, A. R., Hollar, D., & Casey, D. E. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.02.007 · Cited by 1,070
DE HERT, M., COHEN, D., BOBES, J., CETKOVICH‐BAKMAS, M., LEUCHT, S., NDETEI, D. M., NEWCOMER, J. W., UWAKWE, R., ASAI, I., MÖLLER, H., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00036.x · Cited by 870 · cited 2×
“The World Psychiatric Association has drawn up new guidelines on physical health in schizophrenia that highlight the health disparities and the importance of screening for physical co-morbidity (De Hert et al. 2011a, b).”
BackgroundChang, C.-K., Hayes, R. D., Perera, G., Broadbent, M. T. M., Fernandes, A. C., Lee, W. E., Hotopf, M., & Stewart, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019590 · Cited by 714 · cited 1×
“Patients suffering from schizophrenia lose up to 15–25 years of life compared with the general population (Hennekens et al. 2005 ; Kilbourne et al. 2009 ; Chang et al. 2011), mostly from natural causes.”
BackgroundTiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10081224 · Cited by 619
Self-citationTwenty-five year mortality of a community cohort with schizophrenia
Brown, S., Kim, M., Mitchell, C., & Inskip, H. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.067512 · Cited by 601 · cited 9×
“These patients have an excess cardiovascular mortality (Kilbourne et al. 2009 ; Brown et al. 2010).”
BackgroundResultInfluentialRay, K. K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.182 · Cited by 446 · cited 1×
“Although the place of statins in primary prevention for CHD has been questioned (Ray et al. 2010), secondary prevention is effective, and statins reduce mortality among those who have suffered atherosclerotic cardiovascular events (Vrecer et al. 2003) and among type 2 diabetics [Cholesterol…”
BackgroundMitchell, A. J., Delaffon, V., Vancampfort, D., Correll, C. U., & De Hert, M. (2012) · Psychological Medicine · doi:10.1017/s003329171100105x · Cited by 332 · cited 3×
“Moreover, the findings that patients with schizophrenia are less likely to be screened for physical co-morbidities (Morrato et al. 2010; Mitchell et al. 2012) highlight the importance of developing effective screening programmes to identify these co-morbidities and then to manage them appropriately…”
BackgroundLaursen, T. M., Munk-Olsen, T., Agerbo, E., Gasse, C., & Mortensen, P. B. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.61 · Cited by 271 · cited 3×
“A Danish study with a 13-year follow-up period in patients with severe mental illness presenting with heart disease found these individuals to have only negligible excess rates of medical contact for heart disease (Laursen et al. 2009).”
BackgroundLahti, R. A., & Penttilä, A. (2001) · Forensic Science International · doi:10.1016/s0379-0738(00)00300-5 · Cited by 253
Inequitable access for mentally ill patients to some medically necessary procedures
Kisely, S., Smith, M., Lawrence, D., Cox, M., Campbell, L. A., & Maaten, S. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.060482 · Cited by 185 · cited 2×
“Similar findings were reported from Nova Scotia (Kisely et al. 2007).”
ResultCigarette smoking and mortality risk in people with schizophrenia
Kelly, D. L., McMahon, R. P., Wehring, H. J., Liu, F., Mackowick, K. M., Boggs, D. L., Warren, K. R., Feldman, S., Shim, J.-C., Love, R. C., et al. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp152 · Cited by 158 · cited 5×
“Their effectiveness is largely assumed to be the same as in the general population, yet we know that this population has high rates of smoking and drug and alcohol abuse (e.g. Kelly et al. 2011).”
BackgroundResultInfluentialKisely, S., Campbell, L. A., & Wang, Y. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.067082 · Cited by 116
Mitchell, A. J., & Lord, O. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810382056 · Cited by 108
Severe mental illness and mortality of hospitalized ACS patients in the VHA
Plomondon, M. E., Ho, P. M., Wang, L., Greiner, G. T., Shore, J. H., Sakai, J. T., Fihn, S. D., & Rumsfeld, J. S. (2007) · BMC Health Services Research · doi:10.1186/1472-6963-7-146 · Cited by 26 · cited 2×
“…and markedly increased cardiovascular mortality but they receive poorer treatment for their somatic illnesses (Brown et al. 2010 ; Druss et al. 2000, 2001 ; HippisleyCox et al. 2009 ; Kisely et al. 2009 ; Laursen et al. 2009 ; however, see Plomondon et al. 2007 for contradictory findings).”
Background
Cited by
Correll, C. U., Solmi, M., Veronese, N., Bortolato, B., Rosson, S., Santonastaso, P., Thapa‐Chhetri, N., Fornaro, M., Gallicchio, D., Collantoni, E., et al. (2017) · World Psychiatry · doi:10.1002/wps.20420 · Cited by 1,729
Excess early mortality in schizophrenia.
Laursen, T. M., Nordentoft, M., & Mortensen, P. B. (2014) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032813-153657 · Cited by 913
Correll, C. U., Solmi, M., Croatto, G., Schneider, L. K., Rohani‐Montez, S. C., Fairley, L., Smith, N., Bitter, I., Gorwood, P., Taipale, H., et al. (2022) · World Psychiatry · doi:10.1002/wps.20994 · Cited by 686
Self-citationComorbidities and mortality in persons with schizophrenia: a Swedish national cohort study
Crump, C., Winkleby, M. A., Sundquist, K., & Sundquist, J. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12050599 · Cited by 619
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Metadata
- Authors
- Lahti, M., Tiihonen, J., Wildgust, H., Beary, M., Hodgson, R., Kajantie, E., Osmond, C., Räikkönen, K., & Eriksson, J.
- Venue
- Psychological Medicine
- Publisher
- Cambridge University Press (CUP)
- Published
- 2012-03-12
- Volume
- 42
- Issue
- 11
- Pages
- 2275-2285
- ISSN
- 0033-2917 (ISSN-L)
- 1469-8978
- OpenAlex
- W1971351668
- Cited by
- 107
- References
- 18
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.